Utilization of a novel electrochemical 90Sr/90Y generator for the preparation of 90Y-labeled RGD peptide dimer in clinically relevant dose

Radiochimica Acta

Volumn 102, Issue 6, 2014, Pages 523-534

  Chakraborty, Sudipta ^a   Chakravarty, Rubel ^a   Sarma, Haladhar Dev ^a   Pillai, Maroor Raghavan Ambikalmajan ^a   Dash, Ashutosh ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

RGD peptide dimer; Targeted therapy

Indexed keywords

EID: 84896344555     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1515/ract-2013-2158     Document Type: Article

References (49)

1. Chakravarty, R., Dash, A., Pillai, M. R. A.: Availability of Yttrium- 90 from Strontium-90: a nuclear medicine perspective. Cancer Biother. Radiopharm. 27, 621-641 (2012).
2. Montana, R. L., Gonzalez, I.H., Ramirez, A. A., Garaboldi, L., Chinol, M.: Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. Curr. Radiopharm. 5, 253-263 (2012).
3. Chakravarty, R., Dash, A., Pillai, M. R. A.: Electrochemical separation is an attractive strategy for development of radionuclide generators for medical applications. Curr. Radiopharm. 5, 271-287 (2012).
4. Chakravarty, R., Pandey, U., Manolkar, R. B., Dash, A., Venkatesh,M., Pillai, M. R. A.: Development of an electrochemical 90 Sr-90 Y generator for the separation of 90 Y suitable for targeted therapy. Nucl. Med. Biol. 35, 245-252 (2008).
5. Folkman, J.: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995).
6. Mousa, S. A.: Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future 23, 51-60 (1998).
7. Carmeliet, P.: Mechanism of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395 (2000).
8. Jin, H., Varner, J.: Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565 (2004).
9. 3 for angiogenesis. Science 264, 569-571 (1994).
10. Hood, J. D., Cheresh, D. A.: Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100 (2002).
11. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., Schwaiger, M.: Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45, 179-182 (2001).
12. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 28, 551-564 (2003).
13. 3-integrin imaging: a new approach to characterize angiogenesis? Eur. J. Nucl. Med. Mol. Imaging 33, S54-S63 (2006).
14. 3 targeted radiotracers for tumor Imaging. Mol. Pharm. 3, 472-487 (2006).
15. 3 expression. Cancer Metastasis Rev. 27, 631-644 (2008).
16. Cai, W., Chen, X.: Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49, 113S-128S (2008).
17. Danhier, F., Le Breton, A., Préat, V.: RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9, 2961-2973 (2012).
18. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
19. Giannis, A., Rubsam, F.: Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: new drugs in cancer therapy. Angew. Chem., Int. Ed. Engl. 36, 588-590 (1997).
20. 3 antagonists. J. Am. Chem. Soc. 118, 7461-7472 (1996).
21. 3 targeted radiotracers: maximizing binding affinity via bivalency. Bioconj. Chem. 20 (2009) 2199-2213.
22. 3 integrin expression using 18 F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785 (2001).
23. 3-selective tracer 18 F-galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341 (2005).
24. 3 expression in man. Clin. Cancer Res. 12, 3942-3949 (2006).
25. Zhou, Y., Chakraborty, S., Liu, S.: Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics 1, 58-82 (2011).
26. 3 expression. Bioconj. Chem. 17, 1069-1076 (2006).
27. Wang, L., Kim, Y. S., Shi, J., Zhai, S., Jia, B., Liu, Z., Zhao, H., Wang, F., Chen, X., Liu, S.: Improving tumor targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol. Pharm. 6, 231-245 (2009).
28. 3 expression. Mol. Imaging 10, 386-397 (2011).
29. Zhu, Z., Miao, W., Li, Q., Dai, H., Ma, Q., Wang, F., Yang, A., Jia, B., Jing, X., Liu, S., Shi, J., Liu, Z., Zhao, Z.,Wang, F., Li, F.: 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J. Nucl. Med. 53, 716-722 (2012).
30. 3 integrin binding peptides in a nude mice model. Cancer Res. 62, 6146-6151 (2002).
31. Chen, X., Liu, S., Hou, Y., Tohme,M., Park, R., Bading, J. R., Conti, P. S.: MicroPET imaging of breast cancer αv-integrin expression with 64 Cu-labeled dimeric RGD peptides.Mol. Imaging Biol. 6, 350-359 (2004).
32. 3 expression. Eur. J. Nucl. Med. Mol. Imaging 35, 1100-1108 (2008).
33. 3 PET imaging. Eur. J. Nucl. Med. Mol. Imaging 36, 947-957 (2009).
34. Shi, J., Wang, L, Kim, Y. S., Zhai, S., Liu, Z., Chen, X., Liu, S.: Improving tumor uptake and pharmacokinetics of 64 Cu labeled cyclic RGD dimers with Gly3 and PEG4 linkers. Bioconj. Chem. 20, 750-759 (2009).
35. Liu, Z., Liu, S., Wang, F., Liu, S., Chen, X.: Noninvasive imaging of tumor integrin expression using 18 F-labeled RGD dimer peptide with PEG4 linkers. Eur. J. Nucl. Med. Mol. Imaging 36, 1296-1307 (2009).
36. Liu, Z., Wang, F., Chen, X.: Integrin targeted delivery of radiotherapeutics. Theranostics 1, 201-210 (2011).
37. Liu, Z., Shi, J., Jia, B., Yu, Z., Liu, Y., Zhao, H., Li, F., Tian, J., Chen, X., Liu, S., Wang, F.: Two 90 Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol. Pharm. 8, 591-599 (2011).
38. Shi, J., Liu, Z., Jia, B., Yu, Z., Zhao, H., Wang, F.: Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177 Lu-labeled cyclic RGDfK dimer. Amino Acids 39, 111-120 (2010).
39. Luna-Gutiérrez, M., Ferro-Flores, G., Ocampo-García, B., Jiménez-Mancilla, N., Morales-Avila, A. E., León- Rodríguez, L. D., Isaac-Olivé, K.: 177 Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(v)β(3) integrins. J. Label. Compd. Radiopharm. 50, 140-148 (2012).
40. 3- positive breast cancer. Bioconj. Chem. 18, 438-446 (2007).
41. 3 integrin by multimerization of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34, 267-273 (2007).
42. Chakraborty, S., Shi, J., Kim, Y. S., Zhou, Y., Jia, B., Wang, F., Liu, S.: Evaluation of 111 In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconj. Chem. 21, 969-978 (2011).
43. Pandey, U., Dhami, P. S., Jagesia, P., Venkatesh,M., Pillai, M. R. A.: A novel extraction paper chromatography (EPC) technique for the radionuclidic purity evaluation of 90 Y for clinical use. Anal. Chem. 80, 801-807 (2008).
44. Venkatesh,M., Pandey, U., Dhami, P. S., Kannan, R., Achutan, P. V., Chitnis, R. R., Gopalakrishnan, V., Banerjee, S., Samuel, G., Pillai, M. R. A., Ramanujam, A.: Complexation studies with 90 Y from a novel 90 Sr-90 Y Generator. Radiochim. Acta 89, 413-417 (2001).
45. USP monographs: Yttrium Y-90 Ibritumomab Tiuxetan Injection. www.pharmacopeia.cn/v29240/usp29nf24s0-m89430.html. Accessed on May 1, 2013.
46. Therapeutic Radionuclide Generators: 90Sr/ 90 Y and 188 W/ 188 Re generators. IAEA Technical Report Series No. 470, Vienna: IAEA, 2009.
47. Maximum permissible body burden and maximum permissible concentrations of radionuclides in air and water for occupational exposure. National Bureau of Standards Handbook. 69, U. S. Department of Commerce, AFP 160-67; 1959, p. 38.
48. Castillo, A. X., Pérez-Malo, M., Isaac-Olivé, K., Mukhallalati, H., González, E. C., Berdeguez,M. T., Díaz, N. C. Production of large quantities of 90 Y by ion-exchange chromatography using an organic resin and a chelating agent. Nucl. Med. Biol. 37, 935-942 (2010).
49. Castillo, A. X., Isaac-Olivé, K., González, E. C., Beckford, D., Montana, R. L., Alvarez, A.M., Alvarez, E.O.: An adapted purification procedure to improve the quality of 90 Y for clinical use. Radiochim. Acta 97, 739-746 (2009).